A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 (Umbralisib) in Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Umbralisib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors TG Therapeutics Inc
- 03 Jul 2024 Status changed from completed to discontinued. (Reason the study was stopped:Strategic/Business Decision)
- 19 Jul 2021 Status changed from active, no longer recruiting to completed.
- 05 May 2021 Planned End Date changed from 1 Jun 2021 to 1 Jul 2021.